Objective. The aim of this study was to evaluate serum levels of the biochemical markers of bone metabolism: osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (ß-CTx) with the presence of bone metastases detected by whole-body bone scintigraphy in patients with malignant melanoma.
INTRODUCTION
Malignant melanoma is a malignancy of pigment-producing cells (melanocytes) located predominantly in the skin but found also in the eyes, ears, gastrointestinal tract, leptomeninges and oral and genital mucous membranes. Melanoma accounts for only 4% of all skin cancers (1). The incidence of melanoma continues to increase and early detection is the most promising means of decreasing morbidity and mortality (2) . Metastases develop in regional lymph nodes, as satelite or in-transit lesions or in distant organs (3) . The lung is most commonly involved followed by brain, liver, bone marrow, and intestine (4) . Bone marrow metastases of melanoma are rare, include 5 -7 % of patients with disseminated disease but in up to 45 % when an autopsy-staging procedure is performed (5) . Skeletal metastases generally occur in patients with widespread metastatic disease and usually represent a late site of recurrence. Melanoma bone metastases are more frequently in the axial skeleton than appendicular and more is located in the spine. Typical bone metastases are osteolytic with medullary origin. Lesion growth caused erosion and destruction, pathologic fractures and soft-tissue involvement. Atypical skeletal metastases exhibit as a mixed osteolytic-osteoblastic pattern or hardly ever as a completely osteoblastic (6) . Radioisotopes play an important role in the diagnoses of bone metastases. Whole-body bone scintigraphy (WBBS) with technetium-99m methylene diphosphonate (Tc-99m MDP) is widely available and commonly used to detect metastases from malignant tumors because it is more sensitive than X-ray and allows the whole body surveyed (7, 8) . Single photon emission computed tomography/computed tomography (SPECT/CT) imaging with the integration of CT and SPECT gantries has enhanced WBBS by providing accurate lesion localization and characterization of equivocal and solitary bone lesions (9, 10, 11) . The detection of recurrent or residual malignancy after treatment is important to allow for early intervention and to optimize patient survival. 2-deoxy-2-[(18)F]fluoro-D-glucose (18F-FDG) positron emission computed tomography/computed tomography (PET/CT) is indicated for surveillance of malignant melanoma due to it is high sensitivity and specificity for soft-tissue or nodal recurrences and metastases (12) . Whole-body positron emission tomography/magnetic resonance imaging (PET/MRI) is a novel metabolic-anatomic imaging technique, which has been introduced into clinical practice. Integrated whole-body PET/MRI will be a tool to achieve the detection of subcutaneous, bone, liver, and brain metastases in patients with malignant melanoma in a single session (13) . Whole-body magnetic resonance imaging (MRI) has been shown to be the most accurate for detecting metastases in the liver, bone, subcutaneous and intra-peritoneal sites (14) .
Osteocalcin (OC) is a small protein, which is synthesized by the mature osteoblasts and OC is considered as a marker of late phase of bone formation, differentiation of osteoblasts (15, 16) . Beta-carboxyterminal cross-linked telopeptide of type I collagen (ß-CrossLaps, ß-CTx) is being as a degrade product of type I collagen during bone resorption in normal bone metabolism. The determination of ß-CTx is using for monitoring of antiresorptive therapy in women with postmenopause, in patients with osteopenia, with primary and secondary hyperparathyroidism, osteomalacia, Paget s disease and with bone metastases (17, 18) .
The aim of this study was to correlate level of the biochemical markers of bone metabolism, osteocalcin (OC) and beta-carboxyterminal cross-linked telopeptide of type I collagen (ß-CTx) in the serum in comparison with finding during the whole-body bone scintigraphy in patients with malignant melanoma.
MATERIAL AND METHODS
In our study we were analyzing of serum from 14 patients (4 men, 10 women) with malignant melanoma and from 10 persons of control group. The youngest patient was 41 years old, the oldest patient was 79 years old (range ± 60.3). Diagnosed malignant melanoma was localized in 3 cases in region of back, in 4 cases on shoulder, in 3 cases on head, once on forearm, heel, in eye and in 1 case localization of malignant melanoma was unknown. In control group were persons without malignant disease (2 men, 8 women), the youngest was 34 years old, the oldest was 67 years old (range ± 52.3), they were examined by whole-body bone scintigraphy for other reasons (unknown back pain, unknown joint pain). In persons of control group who were examined by whole-body bone scintigraphy, were not detected pathological altered of bone restructuring, which could have influence on levels of the markers of bone metabolism in the serum.
In patients with malignant melanoma we were taking blood from peripheral vein using sterile closed set for sterile vacuum test-tube before intravenous injection the bone-imaging radioactive agent technecium-99m -methylene disphosphonate ( 99m Tc-MDP). The blood we centrifuged at 4000 revolutions/min for 5 minutes. The obtained serum was stored in aliquots at -20°C and -50°C until assayed. Serum OC, ß-CTx were measured with automated electro-chemi-luminescence immunoassay equipment (Elecsys, Roche Diagnostics) at the Department of Clinical Biochemistry.
Examinations of whole-body bone scintigraphy were obtained using a double-head hybrid gamma-camera SPECT/CT with a built-in flat-panel CT detector (BrightView XCT, Philips Healthcare) with a low-energy general-purpose parallel hole collimator (LEGP). The record- Tc -MDP) as a wholebody scan of the skeleton in anterior and posterior projection with scanning speed of 10 -12 centimetre per minute. Planar whole-body image acquisition was performed using a 140 keV technetium photopeak (with a 20 % window). Additional static images (500 kcounts) of the skull (lateral views) were performed in all patients and additional static images (1000 kcounts) of the equivocal areas of the chest or pelvis were acquired in most patients or single photon emission computed tomography/computed tomography (SPECT/CT) (64 steps over a 180° circular orbit with two heads of gamma-camera, 20 -30 se conds per step, 128x 128 matrix) when necessary. X-ray parameters: current 20 -80 mAs, voltage 120 kV, segments of CT 1 or 3 (full spect FOV -field of view) 14.4 or 43.2 cm. SPECT and CT images were fused by software (Extended Brilliance Workspace, Philips Healthcare).
RESULTS AND DISCUSSION
From 14 patients with malignant melanoma 5 patients had evidence of bone metastases, 3 patients probable bone metastases and 6 patients had no evidence of bone metastases on the finding during the whole-body bone scintigraphy. In patients with probable bone metastases will be appropriate to repeat the whole-body bone scintigraphy in four -five months. We divided patients with malignant melanoma according to finding of whole-body bone scintigraphy in 3 groups: definite bone metastases, probable bone metastases, no evidence of bone metastases. In case of probable bone metastases was the finding of lesions which were suspicious for bone metastases and less probable for another lesions. In 8 patients were realized scintigraphy imaging and intraoperative detection of sentinel lymph node (SLN) with gammaprobe during surgery. In 4 cases were SLN present. Later in skeleton were detected bone metastases in 3 cases from 4 patients with metastases in SLN after biopsy during surgery in the past. In 1 patient with SLN, which was without metastases after biopsy (Clark, level of invasion II-III, Breslow thickness 6 millimetre) were detected metastases in the skeleton in period 3.5 years. Positive SLN or subsequent diagnosis of malignant melanoma and thus the subsequent treatment may result in increased risk of bone metastases.
The most often were metastases in the skeleton in melanoma which was localized in region of head (Table 1) . Brountzos et al. reported that skeletal metastases were more frequent in patients with primary melanomas of the trunk and the head and neck area (19) . Back (3) Shoulder (4) Extremities (2) Head (3) Eye (1) Unknown ( Dividing of patients according to finding during the whole-body bone scintigraphy in 3 groups we had made before, we started evaluation of the levels of OC, ß-CTx and correlation of the finding of whole-body bone scintigraphy. We determined serum concentrations of osteocalcin and ß-CTx in patients with malignant melanoma and in control subjects (Fig.  1) . In next step we evaluated the results with the finding of the whole-body bone scintigraphy (Fig. 2, Table 2 ). The markers of bone metabolism were lower ( Fig. 2A, Fig. 2B , and Table 2 ) in patients with definite bone metastases than in control subjects. The serum concentration of OC was below reference range in 4 cases from 5 patients with definite bone metastases and in 1 case was OC concentration in reference range. In 2 patients with no evidence of bone metastases were OC concentrations in the serum lower, too. Other patients with finding probable bone metastases and no evidence bone metastases during the wholebody bone scintigraphy had concentration of OC in reference range. From 5 patients with definite bone metastases were ß-CTx concentration lower in 2 cases and in 1 case in patient with no evidence bone metastases. In other cases were the serum levels of ß-CTx in the serum in reference range. Higher concentrations of OC and ß-CTx in the serum above reference range were not find in patients of observed group. 2 (5) 0 (3) 1 (6) mts -metastases, p -the number of patients with lower level of bone biomarkers in melanoma patients, n -the number of patients with given finding of whole-body bone scintigraphy
A C T A M E D I C A M A R T I N I A N
Human bone is continuously remodelled through a process of bone formation and resorption. The exact function of osteocalcin is still unclear but it is used as a marker of bone formation. Osteocalcin is used in monitoring of antiresorptive treatment for osteoporosis. We can find normal, higher or lower concentration of this bone marker in postmenopausal osteoporotic women (20) and in patients with multiple myeloma (21) . Increased concentration of OC was observed in osteomalacia, hyperparathyroidism, bone fracture and Paget's disease. Some authors similar as we did not observe changes in OC concentration in patients with bone metastases (22, 23, 24) .
Beta-CTx is released into the blood during bone resorption and serves as a specific marker for the degradation of mature type I collagen. Bone turnover may be elevated or decreased during several pathological circumstances. Beta-CTx is used as a marker of bone resorption in monitoring of primary and secondary hyperparathyroidism, Paget's disease, bone metastases and for monitoring of antiresorptive treatment. Zulauf et al. did not observe pathological elevated concentration of β-CTx in patients with malignancy and bone metastases but concentration of β-CTx was higher in patients with breast carcinoma with bone metastasis than patients without tumor (25) . These authors suggested that β-CTx may be a sensitive to detect bone metastases in patients with breast carcinoma.
CONCLUSIONS
The success of the therapy of malignant melanoma is depending of early diagnostics and following therapy. In our preliminary study of patients with malignant melanoma had lower the serum concentrations of the markers of bone metabolism (osteocalcin and beta-carboxyterminal cross-linked telopeptide of type I collagen) than control subjects and the lowest concentration of OC and ß-CTx were in patients with definite bone metastases. The decreasing concentrations of osteocalcin and beta-carboxyterminal cross-linked telopeptide of type I collagen could be of importance in the diagnosis of bone metastases in patients with malignant melanoma, but with correlation of finding during whole-body bone scintigraphy. A further investigation of OC and ß-CTx as markers of bone remodelling is necessary. It can be very interesting to assess for exact assessment of these markers in larger group of patients with malignant melanoma and correlated with finding during the whole-body bone scintigraphy and whole-body positron emission tomography/computed tomography (PET/CT) with 18 F-FDG or whole-body positron emission tomography/magnetic resonance imaging (PET/MRI) with 18 F-FDG.
